Skip to Content

Osigraft

Active Substance: eptotermin alfa
Common Name: eptotermin alfa
ATC Code: M05BC02
Marketing Authorisation Holder: Olympus Biotech International Limited
Active Substance: eptotermin alfa
Status: Withdrawn
Authorisation Date: 2001-05-17
Therapeutic Area: Tibial Fractures
Pharmacotherapeutic Group: Drugs for treatment of bone diseases, bone morphogenetic proteins

Therapeutic Indication

Treatment of nonunion of tibia of at least 9 month duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or use of autograft is unfeasible.

The marketing authorisation for Osigraft has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide